These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 37530610)

  • 1. Cholinesterase Inhibitors for Delusions and Hallucinations in Alzheimer Disease and Parkinson Disease: Questionably Significant Benefits.
    Andrade C
    J Clin Psychiatry; 2023 Jul; 84(4):. PubMed ID: 37530610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin.
    Mathis MV; Muoio BM; Andreason P; Avila AM; Farchione T; Atrakchi A; Temple RJ
    J Clin Psychiatry; 2017 Jun; 78(6):e668-e673. PubMed ID: 28493654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis.
    d'Angremont E; Begemann MJH; van Laar T; Sommer IEC
    JAMA Neurol; 2023 Aug; 80(8):813-823. PubMed ID: 37358841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholinesterase inhibitors for Alzheimer's disease.
    Birks J
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD005593. PubMed ID: 16437532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
    Daiello LA
    Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
    Parsons C; Lim WY; Loy C; McGuinness B; Passmore P; Ward SA; Hughes C
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD009081. PubMed ID: 35608903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
    Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL
    Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donepezil as add-on treatment of psychotic symptoms in patients with dementia of the Alzheimer's type.
    Bergman J; Brettholz I; Shneidman M; Lerner V
    Clin Neuropharmacol; 2003; 26(2):88-92. PubMed ID: 12671528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease.
    Mancini F; Tassorelli C; Martignoni E; Moglia A; Nappi G; Cristina S; Pacchetti C
    Clin Neuropharmacol; 2004; 27(1):33-7. PubMed ID: 15090935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Lenzi GL; Meco G
    Neurol Sci; 2002 Apr; 23(1):41-3. PubMed ID: 12111620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.
    Panchal SC; Ondo WG
    Curr Psychiatry Rep; 2018 Jan; 20(1):3. PubMed ID: 29374325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
    Battle CE; Abdul-Rahim AH; Shenkin SD; Hewitt J; Quinn TJ
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013306. PubMed ID: 33704781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of delusions in Alzheimer's disease--response to pharmacotherapy.
    Fischer C; Bozanovic R; Atkins JH; Rourke SB
    Dement Geriatr Cogn Disord; 2006; 22(3):260-6. PubMed ID: 16902281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence.
    Franco KN; Messinger-Rapport B
    J Am Med Dir Assoc; 2006 Mar; 7(3):201-2. PubMed ID: 16503315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
    Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
    J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pimavanserin evaluated by the FDA.
    Webster P
    Lancet; 2018 May; 391(10132):1762. PubMed ID: 29739555
    [No Abstract]   [Full Text] [Related]  

  • 17. A Randomized Placebo-Controlled Discontinuation Study of Cholinesterase Inhibitors in Institutionalized Patients With Moderate to Severe Alzheimer Disease.
    Herrmann N; O'Regan J; Ruthirakuhan M; Kiss A; Eryavec G; Williams E; Lanctôt KL
    J Am Med Dir Assoc; 2016 Feb; 17(2):142-7. PubMed ID: 26482056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychosis and Clinical Outcomes in Alzheimer Disease: A Longitudinal Study.
    Connors MH; Ames D; Woodward M; Brodaty H
    Am J Geriatr Psychiatry; 2018 Mar; 26(3):304-313. PubMed ID: 29174998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delusions and hallucinations are associated with worse outcome in Alzheimer disease.
    Scarmeas N; Brandt J; Albert M; Hadjigeorgiou G; Papadimitriou A; Dubois B; Sarazin M; Devanand D; Honig L; Marder K; Bell K; Wegesin D; Blacker D; Stern Y
    Arch Neurol; 2005 Oct; 62(10):1601-8. PubMed ID: 16216946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pimavanserin approved for Parkinson's-related hallucinations, delusions.
    Traynor K
    Am J Health Syst Pharm; 2016 Jun; 73(12):853. PubMed ID: 27261226
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.